Dentsply Sirona
XRAY
8.54
+0.02
+0.23%
Dentsply Sirona
US · XRAY
#2904 by market cap
Listed 1970
8.54
+0.02
+0.23%
Live - 5344 symbols - heartbeat 9s ago
· 2026-10-08 08:21
Pre-market
8.48
-0.70%
After-hours
8.41
-1.52%
- Market cap
- 1.70B
- P/E (TTM)i
- -3.13
- P/Bi
- 1.26
- EPSi
- -3.00
- Div yieldi
- 3.75%
- 52W posi
- 3%
Reader sentiment
Are you bullish or bearish on XRAY?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.83, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -2.98% YoY
Margins
- Gross margin
- 50.00%
- Operating margin
- 6.85%
- Net margin
- -16.25%
Key ratios & quality
- Enterprise valuei
- 3.75B
- Altman Z-Scorei
- 0.83
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.99B | 4.02B | 3.34B | 4.23B | 3.92B | 3.97B | 3.79B | 3.68B |
| Gross profit | 2.07B | 2.16B | 1.66B | 2.35B | 2.13B | 2.09B | 1.96B | 1.84B |
| Selling & admin expenses | 1.72B | 1.59B | 1.30B | 1.55B | 1.59B | 1.61B | 1.61B | 1.44B |
| Research & development | -- | 143.00M | 123.00M | 171.00M | 174.00M | 184.00M | 165.00M | 150.00M |
| Operating profit | 349.00M | 434.00M | 231.00M | 625.00M | 364.00M | 289.00M | 188.00M | 252.00M |
| Pretax profit | -958.00M | 338.00M | -50.00M | 545.00M | -1.06B | -175.00M | -936.00M | -486.00M |
| Tax | 53.00M | 82.00M | 23.00M | 134.00M | -105.00M | -43.00M | -26.00M | 112.00M |
| Net profit | -1.01B | 256.00M | -73.00M | 411.00M | -950.00M | -132.00M | -910.00M | -598.00M |
| Basic EPS | -5 | 1 | 0 | 2 | -4 | -1 | -4 | -3 |
| Diluted EPS | -4.51 | 1.14 | -0.33 | 1.87 | -4.41 | -0.62 | -4.48 | -3.00 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 879.00M | 936.00M | 904.00M | 961.00M | 880.00M | 898.00M |
| Gross profit | 466.00M | 490.00M | 441.00M | 443.00M | 427.00M | 493.00M |
| Selling & admin expenses | 360.00M | 344.00M | 358.00M | 378.00M | 353.00M | 365.00M |
| Research & development | 36.00M | 37.00M | 37.00M | 40.00M | 44.00M | 45.00M |
| Operating profit | 70.00M | 109.00M | 46.00M | 25.00M | 30.00M | 83.00M |
| Pretax profit | 44.00M | -153.00M | -230.00M | -147.00M | -42.00M | 72.00M |
| Tax | 25.00M | -109.00M | 198.00M | -2.00M | -32.00M | 36.00M |
| Net profit | 19.00M | -44.00M | -428.00M | -145.00M | -10.00M | 36.00M |
| Basic EPS | 0 | 0 | -2 | -1 | 0 | 0 |
| Diluted EPS | 0.10 | -0.22 | -2.14 | -0.74 | -0.05 | 0.18 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.89B | 2.00B | 1.80B | 1.85B | 1.89B | 1.97B | 1.75B | 2.02B |
| Cash & ST investments | 309.60M | 405.00M | 438.00M | 339.00M | 365.00M | 334.00M | 272.00M | 326.00M |
| Inventory | 598.90M | 562.00M | 476.00M | 515.00M | 627.00M | 624.00M | 564.00M | 642.00M |
| Total assets | 8.69B | 8.60B | 9.35B | 9.24B | 7.64B | 7.37B | 5.75B | 5.43B |
| Total current liabilities | 1.01B | 995.00M | 1.37B | 1.26B | 1.17B | 1.43B | 1.59B | 1.34B |
| Short-term debt | 92.40M | 46.00M | 347.00M | 232.00M | 172.00M | 378.00M | 595.00M | 360.00M |
| Long-term debt | 1.56B | 1.43B | 1.98B | 1.91B | 1.83B | 1.80B | 1.59B | 2.02B |
| Total liabilities | 3,554,000,000.00 | 3,508,000,000.00 | 4,415,000,000.00 | 4,242,000,000.00 | 3,831,000,000.00 | 4,076,000,000.00 | 3,810,000,000.00 | 4,089,000,000.00 |
| Total equity | 5.13B | 5.10B | 4.94B | 5.00B | 3.81B | 3.29B | 1.94B | 1.34B |
| Retained earnings | 1.23B | 1.40B | 1.20B | 1.51B | 456.00M | 205.00M | -835.00M | -1.56B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.98B | 1.97B | 2.07B | 2.02B | 1.85B | 1.93B |
| Cash & ST investments | 398.00M | 359.00M | 363.00M | 326.00M | 190.00M | 239.00M |
| Inventory | 612.00M | 675.00M | 686.00M | 642.00M | 659.00M | 665.00M |
| Total assets | 6.05B | 6.07B | 5.65B | 5.43B | 5.23B | 5.20B |
| Total current liabilities | 1.79B | 1.17B | 1.41B | 1.34B | 1.21B | 1.19B |
| Short-term debt | 742.00M | 184.00M | 378.00M | 360.00M | 230.00M | 228.00M |
| Long-term debt | 1.59B | 2.22B | 2.02B | 2.02B | 2.01B | 2.00B |
| Total liabilities | 4,040,000,000.00 | 4,108,000,000.00 | 4,175,000,000.00 | 4,089,000,000.00 | 3,910,000,000.00 | 3,853,000,000.00 |
| Total equity | 2.01B | 1.96B | 1.48B | 1.34B | 1.32B | 1.35B |
| Retained earnings | -848.00M | -925.00M | -1.39B | -1.56B | -1.57B | -1.54B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 500.00M | 639.00M | 649.00M | 657.00M | 517.00M | 377.00M | 461.00M | 235.00M |
| Depreciation & amortization | 331.00M | 323.00M | 334.00M | 346.00M | 328.00M | 343.00M | 349.00M | 352.00M |
| Free cash flow | 312.00M | 516.00M | 562.00M | 515.00M | 368.00M | 228.00M | 281.00M | 104.00M |
| Dividends paid | -79.00M | -81.00M | -- | -92.00M | -104.00M | -116.00M | -126.00M | -128.00M |
| Stock buybacks / issuance | -250.00M | -260.00M | -228.00M | -200.00M | -150.00M | -300.00M | -250.00M | 0 |
| Ending cash balance | 310.00M | 405.00M | 438.00M | 339.00M | 365.00M | 334.00M | 272.00M | 326.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 7.00M | 48.00M | 79.00M | 101.00M | 40.00M | 99.00M |
| Depreciation & amortization | 79.00M | 88.00M | 92.00M | 93.00M | 79.00M | 85.00M |
| Free cash flow | -12.00M | 16.00M | 40.00M | 60.00M | -12.00M | 55.00M |
| Dividends paid | -32.00M | -32.00M | -32.00M | -32.00M | -32.00M | 0 |
| Stock buybacks / issuance | -- | -- | 0 | 0 | -- | -- |
| Ending cash balance | 398.00M | 359.00M | 363.00M | 326.00M | 190.00M | 239.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -17.23 | 5.15 | -1.65 | 8.41 | -21.46 | -3.72 | -34.77 | -36.45 |
| ROA %i | -10.61 | 3.04 | -0.93 | 4.54 | -11.27 | -1.76 | -13.87 | -10.70 |
| ROIC %i | -13.11 | 4.21 | -0.69 | 6.27 | -13.48 | -1.23 | -17.19 | -13.18 |
| 5-year avg ROE %i | -1.19 | -2.85 | -5.30 | -5.29 | -5.39 | -2.69 | -10.65 | -17.65 |
| EBIT margin %i | -23.11 | 9.30 | -0.36 | 14.44 | -25.37 | -2.37 | -22.86 | -10.82 |
| FCF / sales %i | 7.82 | 12.66 | 16.40 | 12.11 | 9.38 | 5.75 | 7.41 | 2.83 |
| Current ratioi | 1.86 | 2.01 | 1.31 | 1.47 | 1.62 | 1.38 | 1.10 | 1.51 |
| Quick ratioi | 1.00 | 1.24 | 0.83 | 0.91 | 0.90 | 0.76 | 0.55 | 0.79 |
| Debt / assetsi | 19.08 | 18.59 | 26.26 | 24.83 | 28.09 | 31.19 | 39.49 | 45.46 |
| LT debt / equityi | 30.56 | 30.49 | 42.74 | 41.27 | 51.82 | 58.34 | 86.35 | 157.43 |
| Interest coveragei | -24.69 | 12.75 | -0.25 | 11.16 | -16.58 | -1.16 | -12.57 | -4.52 |
| Revenue CAGR (3Y) %i | 14.23 | 2.40 | -5.79 | 2.01 | -0.84 | 5.90 | -3.58 | -2.10 |
| Net income CAGR (3Y) %i | -- | -15.87 | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -9.82 | 5.67 | 7.62 | 18.18 | -10.66 | -25.97 | -18.29 | -34.38 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -34.47 | -37.78 | -44.44 | -36.45 | -37.74 | -32.98 |
| ROA %i | -13.79 | -14.64 | -14.37 | -10.70 | -11.14 | -9.69 |
| ROIC %i | -16.95 | -18.15 | -18.64 | -13.18 | -14.16 | -12.11 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -22.94 | -28.14 | -21.52 | -10.82 | -13.01 | -7.03 |
| FCF / sales %i | 7.48 | 3.76 | 2.21 | 2.83 | 2.83 | 3.93 |
| Current ratioi | 1.10 | 1.69 | 1.47 | 1.51 | 1.53 | 1.63 |
| Quick ratioi | 0.56 | 0.86 | 0.72 | 0.79 | 0.67 | 0.72 |
| Debt / assetsi | 40.05 | 41.09 | 43.87 | 45.46 | 44.58 | 44.43 |
| LT debt / equityi | 83.63 | 117.86 | 142.22 | 157.43 | 159.41 | 154.26 |
| Interest coveragei | -12.19 | -13.42 | -9.51 | -4.52 | -5.15 | -2.81 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Essential Dental Solutions is the largest reported line at 41.87% of revenue, across 4 reported segments.
- No single line clears half of revenue; Connected Technology Solutions is next at 26.61%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Essential Dental Solutions41.87%
Connected Technology Solutions26.61%
Orthodontic and Implant Solutions21.94%
Wellspect Healthcare9.58%
Quote time 2026-10-08 08:21:06 · For reference only, not investment advice and not tailored to your situation.